• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ: CSTL )

27.53 +0.44 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 382,571
Open 26.58
Bid (Size) 27.50 (1)
Ask (Size) 30.69 (1)
Prev. Close 27.09
Today's Range 26.58 - 27.99
52wk Range 16.96 - 35.84
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2024
From Castle Biosciences Inc.
Via Business Wire
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
December 12, 2024
From Castle Biosciences Inc.
Via Business Wire

Performance

YTD
+25.36%
+25.36%
1 Month
-7.65%
-7.65%
3 Month
-8.14%
-8.14%
6 Month
+24.12%
+24.12%
1 Year
+25.54%
+25.54%

More News

Read More
The Analyst Landscape: 4 Takes On Castle Biosciences
October 29, 2024
Via Benzinga
Sotera Health Stock Earns 91 RS Rating
September 10, 2024
Via Investor's Business Daily
Guardant Health Stock Sees RS Rating Jump To 83
November 20, 2024
Via Investor's Business Daily
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
November 20, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
November 19, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
November 08, 2024
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
November 07, 2024
From Castle Biosciences Inc.
Via Business Wire
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
November 06, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Third Quarter 2024 Results
November 04, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
October 29, 2024
From Castle Biosciences Inc.
Via Business Wire
Momentum Has Narrowed Again, Significantly
October 28, 2024
Via Talk Markets
Castle Biosciences to Participate in Upcoming Investor Conferences
October 28, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
October 20, 2024
From Castle Biosciences Inc.
Via Business Wire
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
October 16, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
October 14, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
October 11, 2024
From Castle Biosciences Inc.
Via Business Wire
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
October 09, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
October 02, 2024
From Castle Biosciences Inc.
Via Business Wire
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 27, 2024
From Castle Biosciences Inc.
Via Business Wire
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
September 23, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
September 16, 2024
From Castle Biosciences Inc.
Via Business Wire
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
September 11, 2024
From Castle Biosciences Inc.
Via Business Wire
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 05, 2024
From Castle Biosciences Inc.
Via Business Wire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap